Clinical Trial Update: SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating SHR2554 as maintenance therapy for Peripheral T-cell lymphoma, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• SHR2554

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: PTCL | Phase 2 | Status: NOT_YET_RECRUITING